Immunocore Holdings plc (IMCR)
NASDAQ: IMCR · Real-Time Price · USD
30.64
-0.08 (-0.26%)
Sep 28, 2026, 4:00 PM EDT - Market closed
Immunocore Holdings Revenue
Immunocore Holdings had revenue of $314.85M in the twelve months ending June 30, 2026, down -11.60% year-over-year. In the year 2025, Immunocore Holdings had annual revenue of $400.02M with 28.95% growth.
Revenue (ttm)
$314.85M
Revenue Growth
-11.60%
P/S Ratio
3.66
Revenue / Employee
$822,090
Employees
524
Market Cap
1.58B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 400.02M | 89.81M | 28.95% |
| Dec 31, 2024 | 310.20M | 60.77M | 24.37% |
| Dec 31, 2023 | 249.43M | 75.53M | 43.44% |
| Dec 31, 2022 | 173.89M | 138.04M | 384.99% |
| Dec 31, 2021 | 35.85M | -5.32M | -12.91% |
| Dec 31, 2020 | 41.17M | 7.13M | 20.95% |
| Dec 31, 2019 | 34.04M | 3.91M | 12.98% |
| Dec 31, 2018 | 30.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Innoviva | 440.00M |
| Syndax Pharmaceuticals | 252.25M |
| AnaptysBio | 106.09M |
| Intellia Therapeutics | 59.51M |
| Stoke Therapeutics | 27.59M |
| Taysha Gene Therapies | 5.49M |
| Absci | 1.56M |
IMCR News
- 14 days ago - Immunocore Holdings Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 15 days ago - Immunocore achieves target patient enrollment in TEBE-AM clinical trial - TheFly
- 15 days ago - Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma - GlobeNewsWire
- 18 days ago - Immunocore Holdings Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 weeks ago - Immunocore to present at upcoming investor conferences - GlobeNewsWire
- 5 weeks ago - Immunocore reinstated with an Overweight at JPMorgan - TheFly
- 7 weeks ago - Immunocore price target raised to $43 from $40 at Morgan Stanley - TheFly
- 7 weeks ago - Immunocore Holdings Earnings Call Transcript: Q2 2026 - Transcripts